Todd Harris Biography and Net Worth

CEO of Tyra Biosciences

Todd Harris is Chief Executive Officer of Tyra which he co-founded in August 2018. Prior to co-founding Tyra, Todd co-founded Sienna Biopharmaceuticals, Inc. (SNNA) a clinical-stage biopharmaceutical company where he was Chief Executive Officer and a member of the board of directors. Todd started his career as a consultant at McKinsey & Company in the Health Care Practice Division. Todd currently serves on the board of directors of Primmune Therapeutics, Inc., a biopharmaceutical company focused on the second arm, innate immune system. Todd holds a B.S. in Electrical Engineering from Brigham Young, a M.S. in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology.

What is Todd Harris' net worth?: The estimated net worth of Todd Harris is at least $29.98 million as of October 21st, 2024. Harris owns 1,355,927 shares of Tyra Biosciences stock worth more than $29,979,546 as of December 4th. This net worth evaluation does not reflect any other assets that Harris may own. Additionally, Harris receives an annual salary of $1,070,000.00 as CEO at Tyra Biosciences. Learn More about Todd Harris' net worth.
How old is Todd Harris?: Harris is currently 45 years old. There are 6 older executives and no younger executives at Tyra Biosciences. Learn More on Todd Harris' age.
What is Todd Harris' salary?: As the CEO of Tyra Biosciences, Inc., Harris earns $1,070,000.00 per year. Learn More on Todd Harris' salary.
How do I contact Todd Harris?: The corporate mailing address for Harris and other Tyra Biosciences executives is 2656 STATE STREET, CARLSBAD CA, 92008. Tyra Biosciences can also be reached via phone at 619-728-4760 and via email at [email protected].. Learn More on Todd Harris' contact information.
Has Todd Harris been buying or selling shares of Tyra Biosciences?: Todd Harris has not been actively trading shares of Tyra Biosciences during the last ninety days. Most recently, Todd Harris sold 19,084 shares of the business's stock in a transaction on Monday, October 21st. The shares were sold at an average price of $27.90, for a transaction totalling $532,443.60. Following the completion of the sale, the chief executive officer now directly owns 1,355,927 shares of the company's stock, valued at $37,830,363.30. Learn More on Todd Harris' trading history.
Who are Tyra Biosciences' active insiders?: Tyra Biosciences' insider roster includes Daniel Bensen (COO), Alan Fuhrman (CFO), Todd Harris (CEO), and Gilla Kaplan (Director). Learn More on Tyra Biosciences' active insiders.
Are insiders buying or selling shares of Tyra Biosciences?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 330,261 shares worth more than $5,972,313.26. The most recent insider tranaction occured on November, 21st when Director Robert J More sold 246,871 shares worth more than $4,999,137.75. Insiders at Tyra Biosciences own 15.2% of the company. Learn More about insider trades at Tyra Biosciences.
Information on this page was last updated on 11/21/2025.

Todd Harris Insider Trading History at Tyra Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/21/2024	Sell	19,084	$27.90	$532,443.60	1,355,927
10/17/2024	Sell	15,394	$25.85	$397,934.90	1,418,647
10/15/2024	Sell	10,035	$24.31	$243,950.85	1,467,338
9/30/2024	Sell	500	$24.00	$12,000.00	1,477,373
9/25/2024	Sell	600	$24.01	$14,406.00	1,477,873
9/23/2024	Sell	10,092	$24.13	$243,519.96	1,479,528
9/19/2024	Sell	5,698	$24.31	$138,518.38	1,496,729
6/22/2023	Sell	3,478	$17.04	$59,265.12	1,621,988
6/20/2023	Sell	1,300	$16.53	$21,489.00	1,645,222
6/15/2023	Sell	12,773	$16.13	$206,028.49	1,701,276
6/13/2023	Sell	7,927	$16.00	$126,832.00	1,701,276
3/30/2023	Sell	2,407	$16.02	$38,560.14	1,701,276
3/28/2023	Sell	2,779	$16.00	$44,464.00	1,701,276
3/24/2023	Sell	170	$16.00	$2,720.00	1,701,276
3/22/2023	Sell	4,043	$16.00	$64,688.00	1,701,276

Todd Harris Buying and Selling Activity at Tyra Biosciences

Tyra Biosciences Company Overview

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Today's Range

Now: $22.11

$21.43

$22.13

50 Day Range

MA: $16.14

$12.97

$22.51

2 Week Range

Now: $22.11

$6.42

$22.83

Volume

916,903 shs

Average Volume

466,587 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Todd Harris Biography and Net Worth

What is Todd Harris' net worth?

How old is Todd Harris?

What is Todd Harris' salary?

How do I contact Todd Harris?

Has Todd Harris been buying or selling shares of Tyra Biosciences?

Who are Tyra Biosciences' active insiders?

Are insiders buying or selling shares of Tyra Biosciences?